Last reviewed · How we verify
CD20 CAR-T
At a glance
| Generic name | CD20 CAR-T |
|---|---|
| Sponsor | Shanghai Longyao Biotechnology Inc., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Anaemia
- Neutrophil count decreased
- Fatigue
- Pyrexia
- Nausea
- Oedema peripheral
- Platelet count decreased
- White blood cell count decreased
- Decreased appetite
- Hypokalaemia
- Diarrhoea
- Dry mouth
Key clinical trials
- Study of LYL314 in Aggressive Large B-Cell Lymphoma (PHASE1, PHASE2)
- Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy (PHASE2)
- A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease (PHASE1)
- Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy (PHASE3)
- CAR-T Followed by Bispecific Antibodies (PHASE2)
- A Study of KITE-363 in Participants With Refractory Autoimmune Diseases (PHASE1)
- A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) (PHASE1)
- Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD20 CAR-T CI brief — competitive landscape report
- CD20 CAR-T updates RSS · CI watch RSS
- Shanghai Longyao Biotechnology Inc., Ltd. portfolio CI